Gyre Therapeutics, Inc. Gain (Loss) on Disposition of Assets
Gyre Therapeutics, Inc. (GYRE) reported Gain (Loss) on Disposition of Assets of -$4.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-03-13
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2025-12-31 was -$2.00K, a 200.00% decline year-over-year.
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2025-09-30 was -$1.00K.
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2025-06-30 was -$1.00K.
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2025-03-31 was $0.00.
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2025 was -$4.00K.
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2024 was -$66.00K.
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2022 was $57.19M.
- Gyre Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2017 was -$18.00K, a 100.81% decline from fiscal 2016.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 9 month as first filed | Gain (Loss) on Disposition of Assets 12 month | Gain (Loss) on Disposition of Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$3.00K derived: sum of 2 quarters · filed 2026-03-13 | -$4.00K derived: sum of 3 quarters · filed 2026-03-13 | -$4.00K 10-K · filed 2026-03-13 | ||
| 2025-09-30 | -$1.00K 10-Q · filed 2025-11-07 | -$2.00K derived: sum of 2 quarters · filed 2025-11-07 | -$2.00K 10-Q · filed 2025-11-07 | $0.00 derived: sum of 4 quarters · filed 2026-03-13 | ||
| 2025-06-30 | -$1.00K 10-Q · filed 2025-08-11 | -$1.00K 10-Q · filed 2025-08-11 | $1.00K derived: sum of 3 quarters · filed 2026-03-13 | $1.00K derived: sum of 4 quarters · filed 2026-03-13 | ||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-13 | $2.00K derived: sum of 2 quarters · filed 2026-03-13 | $2.00K derived: sum of 3 quarters · filed 2026-03-13 | -$66.00K derived: sum of 4 quarters · filed 2026-03-13 | ||
| 2024-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $2.00K derived: sum of 2 quarters · filed 2026-03-13 | -$66.00K derived: sum of 3 quarters · filed 2026-03-13 | -$66.00K 10-K · filed 2026-03-13 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$68.00K derived: sum of 2 quarters · filed 2025-11-07 | -$68.00K 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | -$68.00K 10-Q · filed 2025-08-11 | -$68.00K 10-Q · filed 2025-08-11 | ||||
| 2023-09-30 | -$526.00K 10-Q · filed 2024-11-13 | -$526.00K derived: sum of 2 quarters · filed 2024-11-13 | -$526.00K 10-Q · filed 2024-11-13 | $4.74M 10-Q · filed 2023-10-26 | $4.15M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.74M 10-Q · filed 2023-08-14 | $4.68M derived: sum of 3 quarters · filed 2023-08-14 | $4.68M derived: sum of 4 quarters · filed 2023-10-26 | ||
| 2023-03-31 | $4.74M 10-Q · filed 2023-05-15 | $4.68M derived: sum of 2 quarters · filed 2023-05-15 | $4.68M derived: sum of 3 quarters · filed 2023-10-26 | $61.92M derived: sum of 4 quarters · filed 2023-10-26 | ||
| 2022-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$59.00K derived: sum of 2 quarters · filed 2023-10-26 | $57.19M derived: sum of 3 quarters · filed 2023-10-26 | $57.19M 10-K · filed 2023-03-30 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $57.24M derived: sum of 2 quarters · filed 2023-10-26 | $57.24M 10-Q · filed 2023-10-26 | |||
| 2022-06-30 | $57.24M 10-Q · filed 2023-08-14 | $57.24M 10-Q · filed 2023-08-14 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | -$116.00K 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$116.00K 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | -$116.00K 10-Q · filed 2019-05-02 | |||||
| 2017-12-31 | -$18.00K 10-K · filed 2018-03-19 | |||||
| 2016-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $2.23M derived: sum of 2 quarters · filed 2018-03-19 | $2.23M 10-K · filed 2018-03-19 | $1.67M 10-K · filed 2017-03-08 | ||
| 2016-09-30 | $804.00K 10-Q · filed 2017-11-02 | $804.00K 10-Q · filed 2017-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |